Full-Time

In Vivo Technician

Research and Development

Posted on 9/25/2025

Deadline 10/1/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$26.34 - $43.89/hr

+ Overtime + Weekend Pay + Holiday Pay + Other Pay Premiums

No H1B Sponsorship

Groton, CT, USA

In Person

Work Location Assignment: On Premise

Category
Lab & Research (1)
Requirements
  • High school with 2 to 3 years applicable experience (i.e., veterinarian care, laboratory animal care and handling); or
  • Associate's degree, Biological Sciences (or equivalent) with 1-3 years applicable experience
  • >7 yrs of relevant in vivo toxicology study conduct experience
  • A.S., Biological Sciences (or equivalent) with > 3 yrs of relevant in vivo toxicology study conduct experience
  • B.S., Biological Sciences (or equivalent) with > 1 yrs of relevant in vivo toxicology study conduct experience
  • AALAS Certification
  • GxP experience
Responsibilities
  • Performs all regulatory responsibilities in compliance with applicable regulatory standards.
  • Responsible for performing all aspects of the in-life phase of rodent and non-rodent safety studies including study set up, test article administration, animal observation, sample collection, data collection and documentation, data quality control review, and preparation of in-life data for archiving.
  • Read, understand and follow the study protocol and understand connection between study protocol and the electronic data capture system protocol which is based on the study protocol.
  • Serve as Study Technician for studies depending on level and experience.
  • Manage multiple assignments/projects as assigned while maintaining data quality and meeting timelines.
  • Ensure proper supplies and equipment are available and suitable for study conduct functions; generate forms, labels, and other materials needed for study conduct as required.
  • Responsible for use, maintenance and calibration of equipment, e.g. balances, centrifuges.
  • Troubleshoot and solve equipment/technical problems associated with in life study conduct.
  • Communicate with Management, Study Director, Comparative Medicine and support personnel to ensure compliance with all protocol driven activities, high quality animal welfare practices are followed, and to enable proactive adjustment of the protocol by the Study Director in the event of unexpected events or findings.
  • Completes self-review of in-life data for accuracy and completeness against the protocol; appropriately documents and corrects data errors, notifies appropriate study personnel as required.
  • Completes QC review of in-life data collected by others depending on experience and level.
  • Assist in preparing data for QA audits and addressing and drafting responses depending on level and experience.
  • Adheres to all applicable company and unit policies and procedures.
  • Ensures work areas are kept clean and orderly.
  • Meets established timelines for deliverables.
  • Reviews and recommends updates for departmental SOPs, may draft updates to SOPs depending on experience and level.
  • Participates in a culture of continuous improvement within assigned work group.
  • Other activities as delegated by Study Director or Test Facility Management.
Desired Qualifications
  • >7 yrs of relevant in vivo toxicology study conduct experience
  • A.S., Biological Sciences (or equivalent) with > 3 yrs of relevant in vivo toxicology study conduct experience
  • B.S., Biological Sciences (or equivalent) with > 1 yrs of relevant in vivo toxicology study conduct experience
  • AALAS Certification
  • GxP experience

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Berobenatide could create a differentiated obesity franchise if Phase 3 succeeds.
  • The 25-valent pneumococcal vaccine can extend Pfizer's vaccine leadership beyond Prevnar.
  • AI licensing with Chai Discovery may accelerate early-stage drug design and hit rates.

What critics are saying

  • Eliquis, Ibrance, and Xtandi patent expirations will pressure revenue before replacements mature.
  • Berobenatide faces entrenched GLP-1 competition and a costly 10-plus-trial Phase 3 program.
  • Pfizer's oncology strategy depends on late-stage execution across dozens of programs and partnerships.

What makes Pfizer unique

  • Pfizer directs about 40% of R&D into oncology across five tumor areas.
  • Its oncology pipeline spans 50+ programs, 25+ new molecular entities, and 3 modalities.
  • HYMPAVZI is the first subcutaneous non-factor therapy for pediatric hemophilia B ages 6-11.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE